FDA's decision to order safety-related labeling changes for fluoroquinolones, including limitations on use in certain conditions, is in lock step with advisory committee recommendations, but stops short of some experts' call for a class-wide Risk Evaluation and Mitigation Strategy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?